Wierda William G, O'Brien Susan M
Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Semin Oncol. 2006 Apr;33(2):202-9. doi: 10.1053/j.seminoncol.2006.01.014.
Evolution of frontline treatment for patients with chronic lymphocytic leukemia (CLL) has been driven by the objective of increasing complete remission (CR) rates and achieving maximum elimination of leukemia. As a result, effective combination regimens incorporating new agents such as monoclonal antibodies have been developed. Beyond morphologic CR, evaluation for residual disease by multicolor flow cytometry or molecular techniques may provide a tool to assess potentially more effective therapies. Although new prognostic factors correlate with time to treatment and survival have been identified, the utility of these factors in predicting response rates or response duration has not been established. Clearly, strides have been made in developing effective treatments that are improving remission duration with the ultimate goal of improving survival for patients with CLL. Herein, we review the recent progress in frontline therapies for patients with CLL.
慢性淋巴细胞白血病（CLL）患者一线治疗的演变是由提高完全缓解（CR）率和最大程度消除白血病的目标驱动的。因此，已开发出包含单克隆抗体等新药物的有效联合方案。除形态学CR外，通过多色流式细胞术或分子技术评估残留疾病可能提供一种评估潜在更有效疗法的工具。尽管已确定与治疗时间和生存相关的新预后因素，但这些因素在预测缓解率或缓解持续时间方面的效用尚未确立。显然，在开发有效治疗方法方面已取得进展，这些方法正在延长缓解持续时间，最终目标是改善CLL患者的生存率。在此，我们综述了CLL患者一线治疗的最新进展。
